MET and alveolar soft part sarcoma: Targeted therapies toward VEGF, MET signaling, and immune modulation are being studied, and while some clinical trials are agnostic of subclassification in treating soft tissue sarcomas, growing familiarity with recurrent molecular features and implicated pathogenic pathways have led to clinical trials being designed specifically for advanced ASPS (e.g., atezolizumab and bevacizumab, in NCT03141684) [24, 25].